Notably, the anti-fibrosis drugs pirfenidone and nintedanib, which are approved for the treatment of idiopathic pulmonary fibrosis (IPF), appear to work by inhibiting the TGF-β pathway [200, 201]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.